Cover Image

HARDBACK
$59.95



View/Hide Left Panel

Agency for Toxic Substances and Disease Registry, 374-375

Alkaloids, 38, 179, 183, 186-204 (passim), 323-351 (passim)

Allergic reactions, 69-70, 191, 201, 324, 345, 350, 365, 388

American Botanical Council, 72

American Herbal Pharmacopoeia, 68-69

American Herbal Products Association, 69-70, 395

Botanical Safety Handbook, review approach, 51-54, 272

American Pharmaceutical Association’s Practical Guide to Natural Medicines, 61-63, 76

Amino acids, 20, 34, 61, 76

Androgens

melatonin, 377

saw palmetto ingestion by women, prototype monograph, 286, 450-477

Angiogenesis inhibitors, shark cartilage, 211, 281, 282, 381-384

Animal studies, 156-173

adverse event reporting and, 135, 163-164, 172

behavioral toxicity, 158, 159, 166

botanicals, 159-161, 390-391, 437-439, 453, 456, 457-458, 468-470, 476-477

carcinogenicity, 163, 164, 172, 368

chaparral, 390-391, 437-439

chemical components and botanicals, taxonomic relatedness, 187-200 (passim), 210, 211

chromium picolinate, 373, 374

FDA, general, 157, 158, 167-168

Framework review process, 11, 94, 100, 101, 102, 103, 105, 106, 293

prototype safety monographs, 283, 285, 287, 358, 360, 364, 365, 368, 373, 381, 437-439, 453, 456, 457-458, 468-470, 476-477

glucosamine, 275-277, 283, 364, 365

melatonin, 368

oral administration of supplements, 156, 457-458, 468

pharmacokinetics and pharmacodynamics, 159, 161-162, 163, 172, 241-242

Redbook, 157, 158

review approaches, various, 45, 49, 52, 55, 57, 59, 61, 63, 266-267, 312

saw palmetto, 453, 456, 457-458, 468-470, 476-477

teratogenicity, 248-249

veterinary medicine, 159-161, 164, 187-200 (passim)

Assays, see In vitro assays

Attitudes and beliefs

consumer beliefs, general, 22-23, 36

consumer expectations about supplement safety, 23-24

Recommended Dietary Allowance, 31

B

Behavioral toxicity, 484

animal studies, 158, 159, 166

melatonin, 369, 370

prototype monographs, 278, 279, 369, 370

Bioavailability, 114-115, 162, 285, 383

Biological activity/mechanism of action

see also Metabolism and metabolites;

Pharmacokinetics and pharmacodynamics

adverse event reporting, 132, 136

chemically and botanically related substances, 176, 205

DSHEA review approaches, various, 17

functional relatedness of chemicals and related botanicals, 92, 175, 208, 210-212, 279-280, 283, 299, 392, 453, 476-477

Framework review process, 94, 96, 365

prototype safety monographs, 383, 456

glucosamine, 365

historical use of botanicals, 139

integration of data, 256-259

interactions, supplement-induced, 236-244

other review approaches, various, 48, 49, 53, 58, 60, 64

Botanical Safety Handbook, 51-54, 272

Botanicals, 175-214

see also Chaparral;

Chemical components and related botanicals;

Saw palmetto

animal studies, 159-161, 390-391, 437-439, 453, 456, 457-458, 468-470, 476-477



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement